Laura Hutchins named interim director of UAMS Rockefeller Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Laura Hutchins, a hematologist-oncologist at the University of Arkansas for Medical Sciences who specializes in breast cancer, melanoma and brain cancer, has been appointed interim director for the UAMS Winthrop P. Rockefeller Cancer Institute, effective immediately.

She succeeds Peter Emanuel, who recently resigned after leading the institute since 2007. A committee will be formed to conduct a national search for a permanent director.

Hutchins is a professor in the College of Medicine Division of Hematology/Oncology where she was division director from 1998 until September 2013. She also has served as director clinical research at the Cancer Institute since 1998 and has held the Virginia Clinton Kelley Endowed Chair for Clinical Breast Cancer Research since 2007.

She has been a co-investigator on numerous NIH grants including those focused on detection of circulating melanoma cells, and using nanotubes to detect and purge circulating cancer cells.

Her research includes collaborating with Thomas Kieber-Emmons, a fellow scientist to study a UAMS-designed vaccine to prevent the recurrence of breast cancer. That vaccine, now in a phase II clinical trial, is being used in women newly diagnosed with breast cancer to determine if the combination of the vaccine and standard chemotherapy improve the benefit of preoperative therapy.

Hutchins was appointed by the governor to the Arkansas Breast Cancer Research Program Oversight Committee from 2001-2004. From 2004-2012, she was appointed to serve on the state Breast Cancer Control Advisory Board, serving as chairman from 2007-2008.

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login